Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04015700 · ClinicalTrials.gov registry record · Phase 1
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04015700: Active Phase 1 study of Glioblastoma, sponsored by Washington University School of Medicine.
NCT04015700 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 9 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04015700, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.
Primary Outcome
A DLT will be defined as any grade 3 toxicity or greater according to CTCAE v5 considered at least possibly related to study treatment. The DLT observation period begins with Cycle 1 Day 1 (date of first vaccine administration) and continues for 30 days
Conditions Studied
Interventions
- BIOLOGICAL Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics
- DEVICE CELLECTRA®2000 EP Device supplied by Geneos Therapeutics
- DRUG Plasmid encoded IL-12
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2027-09-03 |
| Phase | Phase 1 |
What the registry record for NCT04015700 still lists
NCT04015700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics is the first listed.
NCT04015700 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04015700 about?
NCT04015700 is a clinical study titled "Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma". This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.
What is the current status of trial NCT04015700?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-07-14. Estimated completion is 2027-09-03.
What conditions does trial NCT04015700 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04015700?
The interventions under investigation include: Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics (BIOLOGICAL), CELLECTRA®2000 EP Device supplied by Geneos Therapeutics (DEVICE), Plasmid encoded IL-12 (DRUG).
Who is sponsoring clinical trial NCT04015700?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04015700 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04015700's enrollment target sits among peer trials
9 195th of 199 higher than 4 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI